Luping Liu

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. ncbi SAR of 3,4-dihydropyrido[3,2-d]pyrimidone p38 inhibitors
    Luping Liu
    Department of Medicinal Chemistry, Merck Research Laboratories, PO Box 2000, Rahway, NJ 07065, USA
    Bioorg Med Chem Lett 13:3979-82. 2003
  2. ncbi p38 MAP kinase inhibitors. Part 5: discovery of an orally bio-available and highly efficacious compound based on the 7-amino-naphthyridone scaffold
    Swaminathan R Natarajan
    Department of Medicinal Chemistry, Merck Research Laboratories, PO Box 2000, Rahway, NJ 07065, USA
    Bioorg Med Chem Lett 16:5468-71. 2006
  3. ncbi The three-dimensional structure of MAP kinase p38beta: different features of the ATP-binding site in p38beta compared with p38alpha
    Sangita B Patel
    Department of Global Structural Biology, Merck Research Laboratory, Rahway, NJ 07065, USA
    Acta Crystallogr D Biol Crystallogr 65:777-85. 2009
  4. ncbi p38 MAP kinase inhibitors: metabolically stabilized piperidine-substituted quinolinones and naphthyridinones
    Jianming Bao
    Department of Medicinal Chemistry, Merck and Co, Inc, PO Box 2000, Rahway, NJ 07065, USA
    Bioorg Med Chem Lett 16:64-8. 2006
  5. ncbi Design and synthesis of potent, orally bioavailable dihydroquinazolinone inhibitors of p38 MAP kinase
    John E Stelmach
    Department of Medicinal Chemistry, Merck Research Laboratories, PO Box 2000, Rahway, NJ 07065, USA
    Bioorg Med Chem Lett 13:277-80. 2003

Collaborators

Detail Information

Publications5

  1. ncbi SAR of 3,4-dihydropyrido[3,2-d]pyrimidone p38 inhibitors
    Luping Liu
    Department of Medicinal Chemistry, Merck Research Laboratories, PO Box 2000, Rahway, NJ 07065, USA
    Bioorg Med Chem Lett 13:3979-82. 2003
    ..Modification of N-1 aryl and C-6 arylsulfide in 3,4-dihydropyrido(3,2-d)pyrimidone analogues for the interaction with the hydrophobic pockets in p38 active site is also discussed...
  2. ncbi p38 MAP kinase inhibitors. Part 5: discovery of an orally bio-available and highly efficacious compound based on the 7-amino-naphthyridone scaffold
    Swaminathan R Natarajan
    Department of Medicinal Chemistry, Merck Research Laboratories, PO Box 2000, Rahway, NJ 07065, USA
    Bioorg Med Chem Lett 16:5468-71. 2006
    ..Compound 16 reduced inflammation in animal disease models at EC(50) doses as low as 0.2mpk...
  3. ncbi The three-dimensional structure of MAP kinase p38beta: different features of the ATP-binding site in p38beta compared with p38alpha
    Sangita B Patel
    Department of Global Structural Biology, Merck Research Laboratory, Rahway, NJ 07065, USA
    Acta Crystallogr D Biol Crystallogr 65:777-85. 2009
    ..This difference in size between the two pockets could be exploited in order to achieve selectivity...
  4. ncbi p38 MAP kinase inhibitors: metabolically stabilized piperidine-substituted quinolinones and naphthyridinones
    Jianming Bao
    Department of Medicinal Chemistry, Merck and Co, Inc, PO Box 2000, Rahway, NJ 07065, USA
    Bioorg Med Chem Lett 16:64-8. 2006
    ..They also displayed excellent PK profiles across three animal species. Quinolinone at 10 mpk showed comparable oral efficacy to that of dexamethasone at 1 mpk in a murine collagen-induced arthritis model...
  5. ncbi Design and synthesis of potent, orally bioavailable dihydroquinazolinone inhibitors of p38 MAP kinase
    John E Stelmach
    Department of Medicinal Chemistry, Merck Research Laboratories, PO Box 2000, Rahway, NJ 07065, USA
    Bioorg Med Chem Lett 13:277-80. 2003
    ..58 microM h)...